HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: dc07-2199v1 31/4/776    most recent Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Google Scholar Articles by Koh, K. K. Articles by Shin, E. K. PubMed PubMed Citation Articles by Koh, K. K. Articles by Shin, E. K. Social Bookmarking                What's this?

Simvastatin Improves Flow-Mediated Dilation but Reduces Adiponectin Levels and Insulin Sensitivity in Hypercholesterolemic Patients

¹ Divisons of Cardiology and Laboratory Medicine, Gil Medical Center, Gachon University, Incheon, Korea
² Diabetes Unit, National Center for Complementary and Alternative Medicine, National Institutes of Health, Bethesda, Maryland
³ Department of Statistics, Ewha Womans University, Seoul, Korea
⁴ Weinberg College of Arts and Sciences, Northwestern University, Evanston, Illinois

Address correspondence and reprint requests to Kwang Kon Koh, MD, PHD, FACC, FAHA, Professor of Medicine and Director, Vascular Medicine and Atherosclerosis Unit, Cardiology, Gil Medical Center, Gachon University, 1198 Kuwol-dong, Namdong-gu, Incheon, Korea 405-760. E-mail: kwangk{at}gilhospital.com

OBJECTIVE—We hypothesized that simvastatin may reduce adiponectin levels and insulin sensitivity in hypercholesterolemic patients.

RESEARCH DESIGN AND METHODS—This was a randomized, double-blind, placebo-controlled, parallel study. Age, sex, and BMI were matched. Thirty-two patients were given placebo, and 30, 32, 31, and 31 patients were given daily 10, 20, 40, and 80 mg simvastatin, respectively, during a 2-month treatment period.

RESULTS—Simvastatin doses of 10, 20, 40, and 80 mg significantly reduced total cholesterol (mean changes 27, 25, 37, and 38%), LDL cholesterol (39, 38, 52, and 54%), and apolipoprotein B levels (24, 30, 36, and 42%) and improved flow-mediated dilation (FMD) (68, 40, 49, and 63%) after 2 months of therapy compared with baseline (P < 0.001 by paired t test) or compared with placebo (P < 0.001 by ANOVA). Simvastatin doses of 10, 20, 40, and 80 mg significantly decreased plasma adiponectin levels (4, 12, 5, and 10%) and insulin sensitivity (determined by the Quantitative Insulin-Sensitivity Check Index [QUICKI]) (5, 8, 6, and 6%) compared with baseline (P < 0.05 by paired t test) or compared with placebo (P = 0.011 for adiponectin and P = 0.034 for QUICKI by ANOVA). However, the magnitudes of these percent changes (FMD, adiponectin, and QUICKI) were not significantly different among four different doses of simvastatin despite dose-dependent changes in the reduction of apolipoprotein B levels.

CONCLUSIONS—Simvastatin significantly improved endothelium-dependent dilation, but reduced adiponectin levels and insulin sensitivity in hypercholesterolemic patients independent of dose and the extent of apolipoprotein B reduction.

Abbreviations: CRP, C-reactive protein • FMD, flow-mediated dilation • QUICKI, Quantitative Insulin-Sensitivity Check Index

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?